biote Corp.BTMDEarnings & Financial Report
biote Corp is a healthcare company specializing in personalized bioidentical hormone replacement therapy solutions for adult men and women. It operates primarily in the U.S. market, offering training programs for licensed healthcare providers, along with complementary wellness supplements and diagnostic services to support patient care outcomes.
Revenue
$49.2M
Gross Profit
N/A
Operating Profit
$6.2M
Net Profit
$-7.1M
Gross Margin
N/A
Operating Margin
12.7%
Net Margin
-14.4%
YoY Growth
-0.2%
EPS
$-0.21
biote Corp. Q2 FY2024 Financial Summary
biote Corp. reported revenue of $49.2M (down 0.2% YoY) for Q2 FY2024, with a net profit of $-7.1M (down 37.8% YoY) (-14.4% margin).
Key Financial Metrics
| Total Revenue | $49.2M |
|---|---|
| Net Profit | $-7.1M |
| Gross Margin | N/A |
| Operating Margin | 12.7% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
biote Corp. Q2 FY2024 revenue of $49.2M breaks down across 4 segments, led by Pellet Procedures Product Revenue at $38.4M (78.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pellet Procedures Product Revenue | $38.4M | 78.1% |
| Dietary Supplements | $8.2M | 16.8% |
| Other | $1.4M | 2.8% |
| Disposable Trocars Product Revenue | $1.1M | 2.3% |
biote Corp. Revenue by Segment — Quarterly Trend
biote Corp. revenue by segment across the last 4 reported quarters, showing how each business line (such as Pellet Procedures Product Revenue and Dietary Supplements) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Pellet Procedures Product Revenue | — | — | — | $36.0M |
| Dietary Supplements | — | — | — | $9.3M |
| Disposable Trocars Product Revenue | $1.2M | $1.2M | $1.2M | $1.2M |
biote Corp. Annual Revenue by Year
biote Corp. annual revenue history includes year-by-year totals (for example, 2025 revenue was $192.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $192.2M |
| 2024 | $197.2M |
| 2023 | $185.4M |
| 2022 | $165.0M |
biote Corp. Quarterly Revenue & Net Profit History
biote Corp. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $46.4M | -6.9% | $2.0M | 4.2% |
| Q3 FY2025 | $48.0M | -6.7% | $8.2M | 17.1% |
| Q2 FY2025 | $48.9M | -0.6% | $3.2M | 6.5% |
| Q1 FY2025 | $49.0M | +4.7% | $13.7M | 28.0% |
| Q4 FY2024 | $49.8M | +9.0% | $3.7M | 7.4% |
| Q3 FY2024 | $51.4M | +12.8% | $10.7M | 20.8% |
| Q2 FY2024 | $49.2M | -0.2% | $-7.1M | -14.4% |
| Q1 FY2024 | $46.8M | +4.4% | $-4.2M | -8.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $46.8M | $49.2M | $51.4M | $49.8M | $49.0M | $48.9M | $48.0M | $46.4M |
| YoY Growth | 4.4% | -0.2% | 12.8% | 9.0% | 4.7% | -0.6% | -6.7% | -6.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $160.1M | $92.9M | $101.3M | $122.4M | $123.4M | $104.8M | $111.3M | $107.6M |
| Liabilities | $205.0M | $234.6M | $228.1M | $224.6M | $208.2M | $183.6M | $176.8M | $158.0M |
| Equity | $-36.0M | $-143.2M | $-130.3M | $-105.9M | $-90.0M | $-85.1M | $-72.8M | $-58.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.4M | $9.9M | $15.6M | $12.4M | $6.5M | $7.1M | $14.1M | $7.6M |